NCT04080882

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Platysmal Bands

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.

Conditions

• Platysmal Bands

Interventions

Type	Name	Description
BIOLOGICAL	AbobotulinumtoxinA dose 1	Treatment of platysmal bands
OTHER	Placebo	Treatment of platysmal bands
BIOLOGICAL	AbobotulinumtoxinA dose 2	Treatment of platysmal bands
BIOLOGICAL	AbobotulinumtoxinA dose 3	Treatment of platysmal bands

Timeline

• Start date: 2019-09-25
• Primary completion: 2019-12-30
• Completion: 2020-06-04
• First posted: 2019-09-06
• Last updated: 2022-08-26
• Results posted: 2021-01-22

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study